TP53 and head and neck squamous cell carcinoma: Since p53 mutations occur very frequently in SCCHN and have been linked to shorter overall survival [13], increased risk of local recurrence [14], [15] and radioresistance [16] the combination of radiotherapy with ATO might represent a novel promising therapeutic strategy in SCCHN.